APA (7th ed.) Citation

Kowalski, D. M., Cho, B. C., Lubiniecki, G. M., Kush, D., Lopes, G., Adamchuk, G., . . . Zhou, J. (2019). Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial. The Lancet (British edition), 393(10183), 1819-1830. https://doi.org/10.1016/S0140-6736(18)32409-7

Chicago Style (17th ed.) Citation

Kowalski, Dariusz M., et al. "Pembrolizumab Versus Chemotherapy for Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic Non-small-cell Lung Cancer (KEYNOTE-042): A Randomised, Open-label, Controlled, Phase 3 Trial." The Lancet (British Edition) 393, no. 10183 (2019): 1819-1830. https://doi.org/10.1016/S0140-6736(18)32409-7.

MLA (9th ed.) Citation

Kowalski, Dariusz M., et al. "Pembrolizumab Versus Chemotherapy for Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic Non-small-cell Lung Cancer (KEYNOTE-042): A Randomised, Open-label, Controlled, Phase 3 Trial." The Lancet (British Edition), vol. 393, no. 10183, 2019, pp. 1819-1830, https://doi.org/10.1016/S0140-6736(18)32409-7.